Revlar Diagnostics

Vial labeled COVID-19 Positive

The Problem with Today's Tests

LFA (Lateral Flow Assay)

Fast POC (Point of Care) test, but often (20% to 40% of the time) gives false negative results

PCR (Polymerase Chain Reaction)

​Highly accurate, but can take a day or more for results and are resource intensive, requiring specialized equipment performed in a lab

Technology

The BioSwitch™ Platform

Instantaneous results

PCR-like accuracy without the delay and expense.

We aim to address the weaknesses of existing testing infrastructure.​​

Advanced Testing Platform

Our mission is to transform the diagnostics industry with breakthrough technology to provide users with faster, easy-to-use, lower cost and more accurate testing products.

Our Research

  • The BioSwitch allows for a ‘Lego-like’ configuration of amino acids. This configuration enables the use of a variety of nanobodies as probes, and various reporter molecules and substrates for the signal.

  • The reporter signal can be colorimetric, bioluminescent or fluorescent given the purpose of the test.

  • BioSwitch technology is designed to be capable of detecting many strains of disease-causing viruses, bacteria, and several cancers.

  • Beyond human diagnostics, the BioSwitch has applications for animal husbandry, agriculture, and industrial uses.

Revlar Diagnostics' initial applications of the BioSwitch will diagnose SARS-CoV-2 (COVID-19) and influenza A & B in laboratory, commercial, and consumer settings.

Scientists at University College Dublin, Ireland are developing a novel diagnostic platform for detecting infectious diseases. The platform uses a uniquely designed biosensor in the form of a hinged peptide molecular switch. We call this biosensor the BioSwitch™ and its design employs nanoscale engineering to create accurate and fast diagnostic tests.

Recent results show that the BioSwitch is capable of outperforming previous diagnostic technologies in sensitivity, specificity, and speed. 

Revlar Labs Molecular Hinged Peptide Switch binding to COVID spike epitope demonstration

Our Strategic Partnerships

University College Dublin

Leinco Technologies, Inc.

Toolbox Medical Innovations

Microsoft

Our Development Strategy

With our research partners at University College Dublin in Ireland (UCD), Revlar Diagnostics is developing a new biotechnology for early detection of: 

 

  • COVID-19 and its variants

  • Influenza A & B

  • Aggressive cancers

  • Other transmissible diseases

RevlarDX for iOS

Quickly and accurately validate any of our tests and securely access your results with seamless Apple Wallet and Apple Health integration. 

Testflighting in Q3 2022

Please Wait...

COVID-19 Negative

All done!

Newsroom

December 2021
Revlar Labs is pleased to announce that it has been selected to present at the Biotech Showcase in San Francisco during the 2022 JP Morgan Healthcare week. 

We are pleased to announce that our new President and Chief Executive Officer, Dr. James Erickson, will be showcasing our BioSwitch technology at the 40th annual J.P. Morgan Healthcare Conference. For more information about the conference, click here

September 2021
UCD and Revlar Labs Shortlisted for 2021 Knowledge Transfer Ireland Industry Engagement Award
Stage for KTI Impact Awards

We are very honoured to have been included among the innovative companies recognised by Knowledge Transfer Ireland. We are also very gratified that KTI has spotlighted the groundbreaking work of Dr Donal MacKernan. He and his colleagues at UCD have created innovations at the intersection of physics and biochemistry that we at Revlar believe will make possible advances in medical diagnostics that will result in profoundly important benefits for mankind. Read more here

© 2022 Revlar Diagnostics, powered by Cloudaxa

Sign Up To Our Newsletter

Thanks for submitting!

  • LinkedIn
  • Vimeo
  • Twitter

Revlar Diagnostics LLC

3130 Alpine Road, STE 288-410, Portola Valley, CA 94028-7549

Get in Touch

Thanks for submitting!